Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Amortizatization of Intangibles (2021 - 2025)

ARS Pharmaceuticals' Amortizatization of Intangibles history spans 5 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles fell 35.04% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $5.5 million, down 24.66%, while the annual FY2025 figure was $5.5 million, 23.86% down from the prior year.
  • Amortizatization of Intangibles for Q4 2025 was $1.0 million at ARS Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $5.9 million in Q2 2024 and bottomed at -$2.0 million in Q1 2024.
  • The 5-year median for Amortizatization of Intangibles is $285000.0 (2021), against an average of $262133.3.
  • The largest annual shift saw Amortizatization of Intangibles crashed 705.96% in 2023 before it surged 434.7% in 2024.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $243000.0 in 2021, then grew by 17.28% to $285000.0 in 2022, then tumbled by 705.96% to -$1.7 million in 2023, then surged by 189.4% to $1.5 million in 2024, then tumbled by 35.04% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Amortizatization of Intangibles are $1.0 million (Q4 2025), $1.1 million (Q3 2025), and $1.5 million (Q4 2024).